The company announced the publication of a study titled, "Clinical classification in low back pain: best-evidence diagnostic rules based on systematic reviews."1 The article, published in the journal BMC Musculoskeletal Disorders, is the first comprehensive systematic review of diagnostic accuracy studies. The goal of the study was to develop clinical diagnostic rules for identifying the most common disorders of the lumbar spine.
The focus of the review was to outline the diagnostic value of signs and symptoms for use in primary care without access to additional more expensive and invasive confirmatory tests. The intent was to provide an evidence-based clinical diagnosis with acceptable accuracy that may reduce the need for invasive or expensive diagnostic methods. In a primary care setting, the clinical prediction rule for the diagnosis of SI joint pain, using a cluster of three of five positive provocative maneuvers in the absence of known discogenic or radicular pain, and dominant pain localized over the posterior superior iliac spine (PSIS), are as good or in most cases better than the clinical prediction rules for other lumbar spine conditions.
“The takeaway of this review is that physical exam findings for the SI joint are more predictive of a positive SI joint block than most other physical exam tests for other low back conditions,” said Mark Laslett, Ph.D., one of the study authors. “While controlled and guided intra-articular SI joint blocks are the best reference standard test for intra-articular SI joint pain, positive provocation SI joint tests in patients known to have no other obvious source of pain, is a reliable and validated diagnostic process that primary care clinicians can predicate referral for surgical opinion and more invasive diagnostic workup.”
The SI joint has been attributed as a source of pain in 15 percent to 30 percent of patients with chronic low back pain,2-5 and in up to 43 percent of patients with new onset or persistent low back pain after lumbar fusion.6 Patients with SI joint disorders may feel pain in the lower back, buttocks and/or legs localized over the posterior superior iliac spine (PSIS). This can be especially true while transitioning from sitting to standing, stepping up or down, bending and lifting, walking, sleeping or even just sitting on the affected side.
SI joint pain is often misdiagnosed or misattributed to other causes, as not all healthcare providers evaluate the SI joint, and most patients do not ask about it. SI joint disorders can be identified through a series of simple tests that include when a patient identifies their pain by pointing directly to the PSIS (the bony prominence overlying the SI joint), known as the Fortin Finger Test. The diagnosis is confirmed with an appropriate physical examination and image-guided diagnostic injections directly in the SI joint.
The iFuse Implant System provides a minimally invasive surgical solution to fuse the SI joint using triangular titanium implants that create an interference fit within the ilium and sacrum. The triangular implant shape and press fit insertion technique are both patented and designed to provide immediate fixation by minimizing the SI joint’s unique motion of nutation. The implants have a porous surface that provides an environment conducive to ongrowth and ingrowth,7 facilitating long-term fusion of the joint. The iFuse Implant, marketed since 2009, is the only commercially available SI joint fusion device in the United States with published prospective clinical evidence from multiple studies that demonstrate improvement in pain, patient function and quality of life.
The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than six months. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.
SI-BONE Inc. develops, manufactures, and commercializes minimally invasive surgical devices for the treatment of patients with low back symptoms related to certain sacroiliac joint disorders. SI-BONE first received 510(k) U.S. Food and Drug Administration clearance to market its iFuse Implant System in November 2008. The CE mark for European commercialization was obtained in November 2010. The company is based in San Jose, Calif.
1. Petersen, et al. Clinical classification in low back pain: best-evidence diagnostic rules based on systematic reviews. BMC Musculoskeletal Disorders. 2017; 18:188
2. Bernard TN, Kirkaldy-Willis WH. Recognizing specific characteristics of nonspecific low back pain. Clin Orthop Relat Res. 1987;217:266–80.
3. Schwarzer AC, Aprill CN, Bogduk N. The Sacroiliac Joint in Chronic Low Back Pain. Spine. 1995;20:31–7.
4. Maigne JY, Aivaliklis A, Pfefer F. Results of Sacroiliac Joint Double Block and Value of Sacroiliac Pain Provocation Tests in 54 Patients with Low Back Pain. Spine. 1996;21:1889–92.
5. Sembrano JN, Polly DW Jr. How Often is Low Back Pain Not Coming From The Back? Spine. 2009;34:E27–32.
6. DePalma M, Ketchum JM, Saullo TR. Etiology of Chronic Low Back Pain Patients Having Undergone Lumbar Fusion. Pain Med. 2011;12:732–9.
7. MacBarb, et al., “Fortifying the Bone-Implant Interface Part II: An In Vivo Evaluation of 3D-Printed and TPS-Coated Triangular Implants,” Int J Spine Surg, 2017; 11.